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Rheumatoid arthritis is the most common autoimmune arthritis in adult population.This disease is characterized by joint damage
and systemic involvement that lead to general physical and mental impairment with consequent worsening of quality of life.
Rheumatoid arthritis is also associated with a large economic burden to healthcare systems. The evidence from the literature
indicates that, despite available treatments, several unmet needs still interfere with rheumatoid arthritis management. Based on
this evidence, some of the unmet medical needs currently present in the management of the rheumatoid arthritis were identified
and a Delphi questionnaire was submitted to 60 Italian Rheumatologists. The aim of this Delphi was to achieve a broad consensus
on the most relevant unmet needs identified, in order to present the Italian reality in view of the availability of new molecules that
could provide an effective therapeutic option in the treatment of patients with rheumatoid arthritis.
1. Introduction
Rheumatoid arthritis (RA) is themost common autoimmune
arthritis in adult population, with an estimated prevalence of
0.3-1% worldwide. [1] An analysis of Italian epidemiological
data shows an overall prevalence of 0.48%. [2]
Joint damage and systemic involvement of RA lead to
general impairment of physical and mental, as well as of
psychological wellbeing, with a consequent worsening of
quality of life (QoL). [1] Furthermore, RA is associated
with a large economic burden to the healthcare systems.
In particular, persistence of pain, loss of productivity, and
impairment of quality of life are linked to an increase of
indirect and intangible costs of the disease. [1]
The evidence from the literature indicates that, despite
available treatments, several unmet needs still interfere
with RA management [3, 4]. Concerning symptoms, many
patients with RA experience unbearable levels of pain and
are not satisfied with their physical functioning outcomes,
despite ongoing treatment [1]. In the longitudinal obser-
vational BARFOT study (Better Anti-Rheumatic Pharma-
cOTherapy), patients with RA diagnosed in the 1990s were
compared with those diagnosed in the 2000s; no differences
between groups were found with regard to pain, patients’
global health, and functional disability (assessed with HAQ)
despite the new available therapies [5]. Furthermore, many
patients with RA still experience unacceptable levels of
fatigue even during intensive treatment. Clinical trials have
demonstrated that even biologics in combination with MTX
do not lead to significant improvements in fatigue. Fatigue
is a determinant of quality of life and it continues to have a
negative impact on more than 50% of patients with RA [1].
Together with physical functioning, mental health is often
impaired in patients with RA. Both mental and physical
impairment have a negative impact on working ability.Thirty
percent of patients leave work prematurely due to the burden
of the illness and, after 5 years from diagnosis, 30-40% of RA
patients manifest disability. [1]
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Remission is the primary target in RA management,
even though there is a high heterogeneity in the definition
of disease remission in clinical practice. In addition to the
concepts of clinical and radiological remission, the new
insight into tissue and molecular heterogeneity and the
presence of nonresponders to available therapies emphasizes
the importance of also including the concept of persistently
active disease [6] that needs to be overcome by the new
treatments.
The EULAR guidelines recommend MTX as first-line
treatment in monotherapy and if response is not achieved,
a switch to biologics or combination of conventional ther-
apies is recommended. [7] Combination therapy with TNF
inhibitors (TNFi) and csDMARD (conventional synthetic
DMARDs) is more effective than TNFi in monotherapy both
in MTX naı¨ve patients and in those who fail MTX therapy,
while maintaining the same safety profile. Importantly com-
bination therapy reduces immunogenicity and progression of
structural damage. However, this varies considerably among
the different biologics. [8] In clinical practice, approximately
a third of RA patients do not use combination therapy and
take bDMARD only, as a monotherapy; the reasons are
mainly due to intolerance and low adherence toMTXor other
csDMARD [8].
Low adherence may lead to suboptimal response to
treatment, late recovery, disease progression, and the need
for a more aggressive therapy with the risk of adverse events.
[9]. Several elements could have an impact on adherence.
Therapeutic strategies based on more than three DMARDs
are associated with a higher risk of low adherence and low
persistence on therapy, compared tomonotherapy withMTX
(P≤ 0.02) [8].
Regardless of adherence, clinical response to treatment
varies between individuals and it is not easy to predict. The
underlying mechanisms of nonresponse are probably linked
to the heterogeneity of the disease itself. Heterogeneity is
not only clinical but also linked to the pathogenic pathways
responsible for the disease in a given patient. For this reason,
the need to develop predictive instruments of therapeutic
response and personalized therapies, choosing the most
efficacious and safest drug, for each patient even in long-term
treatment, has been highlighted [10].
Based on this evidence, we identified some of the unmet
medical needs currently present in the management of the
RA.The aim of this project was to achieve a consensus within
a group of expert Italian rheumatologists on themost relevant
unmet needs identified, in order to depict the Italian reality in
viewof the availability of newmolecules that could provide an
effective therapeutic option in the treatment of patients with
RA.
2. Methods
A stepwise approach was used:
(a) A selection of the relevant literature of the last 10
years, concerning unmet medical needs in the man-
agement of the RA, was carried out.This selectionwas
shared among and validated by a board of experts.The
board included clinicians with several years’ experi-
ence in the field of RA from different Italian areas
and, hence, representative of the Italian rheumatology
community. Among the selected papers, the most
relevant unmet needs, recognized by the international
scientific community, were identified in the following
9 areas: (1) optimal pain control; (2) significant
fatigue improvement; (3) satisfactory levels of phys-
ical functioning; (4) maintain workability; (5) social
functioning; (6) treatment adherence; (7) prognostic
factors of treatment response; (8) best conditions for
an effective monotherapy; (9) disease remission.
(b) A first Delphi (1) round among the board compo-
nents: the board ranked the identified areas according
to a 5-point Likert scale, based on research evidence
and their clinical judgment. In each area, a list of
statements was identified. Finally, the list of the
proposed statements was reviewed and approved, to
then submit to six rheumatologists, experts in RA
treatment. After the evaluators’ feedback and com-
ments, the final questionnaire was prepared, where
each unmet need was detailed in 1 or 2 statements
and each statement was then extended into 4 or
more specific items, as specified in the results section.
(Tables 1–5)
(c) A second Delphi round: The questionnaire was then
sent to 60 Italian rheumatologists, with consolidated
experience in RA treatment, using a modified Delphi
method [1], in order to reach a consensus. All the
experts were requested to have been working in a
tertiary rheumatology center, having full access to
all the marketed biologic drugs, being authors or
coauthor of papers dealing with RA published on
peer-reviewed journals over the last 15 years. They
expressed their level of agreement according to the
following 5-point Likert scale: 1 = strongly disagree,
2 = disagree, 3 = agree, 4 = more than agree, and 5 =
strongly agree. Consensus was reached when the sum
of items 1 and 2 (Disagree) or that of 3, 4, and 5 (Agree)
reached 66%. No consensus was reached, when the
sum of the responses for a negative consensus (1 and
2) or a positive consensus (3, 4, and 5) was <66%.
3. Results
Forty-eight out of the 60 questionnaires sent were completed.
Panelists’ agreement on statements was very high from the
very beginning of the Delphi Study.
Answers to the Delphi questionnaire are shown in Tables
1–5.
Consensus was reached for the majority of the proposed
statements. However, neither positive nor negative consensus
was found in three cases (items 4.5, 8.3, and 8.4). (Tables
2 and 4) This may reflect a shared common view of Italian
rheumatologists on the topics. In few cases consensus was
reached with a lower percentage of agreement.
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Table 1: Answers to the Delphi questionnaire (Items 1 and 2). The table shows the Delphi questionnaire and the answers relating to the
individual items. The answers given by the Delphi participants are expressed in numerical terms. The percentages indicate the sum of the
answers related to nonconsensus (1, 2) and consensus (3, 4, and 5).
Optimal pain control
1. Pain plays an increasingly important role in the patients’ perception of the severity of the disease. erefore, to obtain
adequate pain control, I deem it is necessary to evaluate the following PROs (patient reported outcomes):
1 2 3 4 5
1.1 Mood 1 1 9 18 19
4% 96%
1.2 Fatigue 2 1 8 22 15
6% 94%
1.3 Physical functioning 2 1 6 16 23
6% 94%
1.4 Sleep disturbances 3 5 7 17 16
17% 83%
2. Current available therapies are not always able to improve pain. Selection of elements to consider for optimal pain control.
erefore, for optimal control of pain, I consider important:
1 2 3 4 5
2.1 to achieve clinical remission 1 0 0 17 30
2% 98%
2.2 to use DMARDs for quick
pain control 1 1 4 24 18
4% 96%
2.3 The use of appropriate
anti-inflammatory analgesics,
including the use of
glucocorticosteroids at the lowest
possible dose and for the shortest
period as possible.
1 0 4 20 23
2% 98%
2.4 psychological / educational
support provided by the doctor
to the patient
1 1 14 19 13
Abbreviations. PROs: patient reported outcomes; DMARD: disease-modifying antirheumatic drug
The experts involved in the study agreed that, for optimal
pain control, a drug therapy, based on DMARDs and anti-
inflammatories (associated with corticosteroids) and psycho-
logical/educational support, is both necessary.
Participants agreed that, in order to optimize physical
functioning, the treat to target therapy is needed. However,
they did not agree with regard to the chronic use of low doses
of corticosteroids in association with DMARDs. This reflects
the EULAR recommendations.
As far as the prognostic factors are concerned, the
interviewed clinicians mainly focused on clinical factors. In
fact, the consensus was not reached on the use of specific
biomarkers (SNPs, micro-RNA, polymorphisms, etc.) or on
the possible presence of antidrug antibodies if the patient was
a secondary failure.
With regard tomonotherapy, a lesser degree of agreement
was reached on the use of bDMARD monotherapy or
tsDMARD (targeted synthetic DMARDs) to remedy the high
proportion of patients who withdraw fromMTX intake.
Concerning the concept of remission, participants identi-
fied all criteria proposed (clinical, radiological, and immuno-
logical) as criteria to be reached in order to achieve complete
remission.
Regarding the remission criteria used in clinical practice,
almost all clinicians agree on the use of SDAI or CDAI and
DAS. They also agree on the use of composite criteria but to
a lesser extent.
4. Discussion
The primary goal of this Delphi consensus study was to
identify the unmet medical needs in the management of
patients with RA in Italy. The analysis of literature pertaining
to this topic highlighted that, despite recent advances in both
diagnosis and treatment of rheumatic diseases, several unmet
needs are still present in RA management [1, 3, 4].
The results of this Delphi consensus confirm that the
above evidence is also applicable to Italy. Consensus was
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Table 2: Answers to the Delphi questionnaire. (Items 3 and 4). The table shows the Delphi questionnaire and the answers relating to the
individual items. The answers given by the Delphi participants are expressed in numerical terms. The percentages indicate the sum of the
answers related to nonconsensus (1, 2) and consensus (3, 4, and 5).
Signiﬁcant fatigue improvement
3. Fatigue continues to have a signiﬁcant negative impact on over half of patients with RA, and it is a factor that impacts on
patient's quality of life. I think that:
1 2 3 4 5
3.1 Only in a certain percentage of
patients fatigue is related to the
progression of the disease
1 8 15 19 5
19% 81%
3.2 Fatigue is not always a valid
indicator to evaluate the effectiveness
of a therapy
1 5 13 17 12
13% 87%
3.3 The FACIT-fatigue (Functional
Assessment of Chronic Illness –
fatigue) in Italian is a valid index to
monitor the fatigue
1 2 24 17 4
6% 94%
3.4 It is correct to include the extent of
fatigue in clinical trial 1 1 17 20 9
4% 96%
3.5 Fatigue can correlate significantly
with mood 1 0 8 16 23
2% 98%
Satisfactory levels of physical functioning
4. Physical functioning levels depend on disease activity, structural damage and fatigue. Current therapies do not oen provide
satisfactory levels of physical functioningerefore to improve physical functioning I consider important:
1 2 3 4 5
4.1 Intervening at an early stage with
second-level drugs (bDMARDS o
tsDMARDs)
2 0 6 20 20
4% 96%
4.2 Implementing a T2T strategy with
closer monitoring 1 0 4 19 24
2% 98%
4.3 Improving adherence to therapy in
order to have optimal control of the
disease
1 0 4 19 24
2% 98%
4.4 Starting a joint education program
immediately after the onset of the
disease
1 1 17 16 13
4% 96%
4.5 Always administering a low dose of
cortisone in association with
DMARDs
4 13 23 6 2
35% 65%
4.6 Administering a low dose of
cortisone in association with DMARD
for a limited period
1 4 12 14 17
10% 90%
Abbreviations. RA: rheumatoid arthritis; FACIT-fatigue: Functional Assessment of Chronic Illness–fatigue; bDMARD: biologic disease-modifying
antirheumatic drug; tsDMARD: targeted synthetic disease modifying anti-rheumatic drug; T2T: treat to target.
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Table 3: Answers to the Delphi questionnaire. (Items 5 and 6). The table shows the Delphi questionnaire and the answers relating to the
individual items. The answers given by the Delphi participants are expressed in numerical terms. The percentages indicate the sum of the
answers related to nonconsensus (1, 2) and consensus (3, 4, and 5).
Maintain workability
5. One third of subjects with RA stop working at an early age. 30-40% of the patients show disability aer 5 years of diagnosis.
e desire to return to a normal working life is one of the main goals from the patient’s perspective. I believe that to achieve
this goal it is important:
1 2 3 4 5
5.1 Diagnosis and early treatment
to avoid disability 1 0 1 8 38
2% 98%
5.2 To Improve adherence to
therapy 1 1 4 18 24
4% 96%
5.3 To include the preservation of
productivity as an integral part of
the therapeutic goals of treatment
0 1 8 18 21
2% 98%
5.4 To Evaluate the patient's work
productivity / inability to work at
least every six months in normal
clinical practice
0 3 16 19 10
6% 94%
Social Functioning
6. Although the “desire for normality” is very important for patients with RA, the aspect of social functioning has never been
the main focus of RA publications.erefore I think that in order to take into account the patients' perspective, it is
appropriate
1 2 3 4 5
6.1 To include the return to a
normal social life among the
treatment goals
0 1 7 24 16
2% 98%
6.2 Use the SF-36 for global
evaluation of the QoL 1 3 23 16 5
8% 92%
6.3 Include the evaluation of
social functioning in the
objectives of clinical trials
0 2 18 20 8
4% 96%
6.4 The sharing between doctor
and patient of the possible
impact of therapy on social life
0 1 6 22 19
2% 98%
Abbreviations. RA: rheumatoid arthritis; SF-36: short form 36; QoL: quality of life.
reached for almost all statements with few exceptions.
Statements that did not reach consensus (4.5, 8.3, and 8.4)
(Tables 2 and 4) will be discussed below. Furthermore, some
controversial aspects in the management of RA that have
reached a lower degree of consensus will be discussed (10.3)
(Table 5).
Physical Functioning (Table 2). Statement 4.6. Physical func-
tioning levels depend on disease activity, structural damage,
and fatigue. Current therapies do not often provide satis-
factory levels of physical functioning. Therefore, to improve
physical function, I always consider adding glucocorticoid at
a low dose to DMARDs treatment.
The answers to the questionnaire were consistent with
EULAR guidelines that recommend that short-term gluco-
corticoids should be considered when initiating or changing
csDMARDs but should be tapered as rapidly as clinically
feasible, due to the potential risk of adverse events [7].
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Table 4: Answers to the Delphi questionnaire. (Items 7 and 8). The table shows the Delphi questionnaire and the answers relating to the
individual items. The answers given by the Delphi participants are expressed in numerical terms. The percentages indicate the sum of the
answers related to nonconsensus (1, 2) and consensus (3, 4, and 5).
treatment adherence
7. Adherence to DMARD is oen suboptimal in RA patients. Poor adherence can reduce the eﬀectiveness of any treatment.
erefore I believe that the factors that can inﬂuence therapeutic adherence are:
1 2 3 4 5
7.1 A shared decision between
doctor and patient about drug
treatment
1 1 1 14 31
4% 96%
7.2 The mode of administration
of the drug 0 3 14 19 12
6% 94%
7.3 The frequency of
administration of the drug 1 3 15 16 13
8% 92%
7.4 Rapid improvement of
symptoms 1 2 5 13 27
6% 94%
7.5 Side effects 1 0 4 15 28
2% 98%
7.6 Patient involvement in
specific programs 1 4 18 11 14
10% 90%
Prognostic factors for treatment response
8.ere are no clear prognostic factors for response to therapies. in the choice of treatment I rely on:




mass index and life habits
0 0 8 22 18
0% 100%
8.2 The presence of any
comorbidity 1 0 2 15 30
2% 98%
8.3 The prevalent biological
pathway to choose the most
suitable MoA drug by searching
for specific biomarkers (SNPs,
micro-RNA, polymorphisms,
etc.)
5 14 12 11 6
40% 60%
8.4 The possible presence of
anti-drug antibodies if the
patient is a secondary failure
6 17 9 10 6
48% 52%
8.5 The MOA of biological drugs
administered before 0 5 9 18 16
10% 90%
Abbreviations.DMARD: disease-modifying antirheumatic drug; RA: rheumatoid arthritis; MoA:mechanism of action; SNPs: single nucleotide polymorphism;
RNA: ribonucleic acid.
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Table 5: Answers to the Delphi questionnaire. (Item 9, 10 and 11). The table shows the Delphi questionnaire and the answers relating to the
individual items. The answers given by the Delphi participants are expressed in numerical terms. The percentages indicate the sum of the
answers related to non-consensus (1, 2) and consensus (3, 4 and 5).
Best condition for an eﬀective mono-therapy
9. In “real life” a high percentage (30-50%) of patients that are undergoing combination therapy with bDMARD and
methotrexate, only take bDMARD, which leads to an expected reduction in therapeutic eﬃcacy.erefore to avoid this you
would need to:
1 2 3 4 5
9.1 Preferentially use bDMARDs
that are effective in monotherapy 1 11 14 14 8
25% 75%
9.2 Use tsDMARDs preferentially 1 11 17 14 5
25% 75%
9.3 Choose drugs with lower risk
of onset of immunogenicity 1 9 13 19 6
21% 79%
9.4 Implement follow-up
programs even at home 2 6 16 20 4
17% 83%
Disease remission
10.e “treat to target” approach has been proposed since 2010 for RA patients, with remission as the best treatment outcome
possible. However, high heterogeneity in the deﬁnitions of disease remission exists in clinical practice. I believe that to achieve
complete remission it would be necessary to reach:
1 2 3 4 5
10.1 Clinical remission 1 0 5 9 33
2% 98%
10.2 Radiological remission
(imaging) 0 2 10 10 26
4% 96%
10.3 Immunological remission 3 9 15 11 10
25% 75%
11. In clinical practice, the state of the disease evaluation is subjected to various criteria. In assessing clinical remission I rely
on:
1 2 3 4 5
11. a.SDAI (simplified disease
activity index) or CDAI (clinical
disease activity index), Boolean
remission
1 2 14 15 16
6% 94%
11.2 DAS28-ESR or DAS28-CRP 1 3 11 16 17
8% 92%
11.3 Ultrasonographic
investigations 3 3 17 11 14
13% 87%
11.4 Composite indexes, which
also take into account the
patient's point of view (PROs)
3 5 19 14 7
17% 83%
Abbreviations. bDMARD: biologic disease-modifying antirheumatic drug; tsDMARD: targeted synthetic disease modifying antirheumatic drug; RA:
rheumatoid arthritis; SDAI, Simplified Disease Activity Index; CDAI: Clinical Disease Activity Index; DAS-28-ESR: Disease Activity Score 28 erythrocyte
sedimentation rate; DAS28-CRP: Disease Activity Score 28 C-reactive protein. PROs: patient reported outcomes.
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The use of steroids in combination with csDMARD is
justified as they have a supportive role for the efficacy of csD-
MARD in the early stages of treatment, until the csDMARD
reaches itsmaximumeffect.With the availability ofmolecules
characterized by faster action, it can be hypothesized that
there will be changes in the use of steroids in patients with
RA. The most recent EULAR guidelines already state that
glucocorticoids are typically not needed as a bridging therapy
when drugs with a rapid onset of action (bDMARDs or
tsDMARDs) are used and their association can increase the
risk of infections [7]. Only clinical practice, in the coming
years, will confirm this hypothesis.
Prognostic Factors for Treatment Response (Table 4). State-
ments 8.3 and 8.4. There are no clear prognostic factors for
response to therapies. In the choice of treatment, I rely on
the prevalent biological pathway to choose the most suitable
MoAdrug by searching for specific biomarkers (SNPs,micro-
RNA, polymorphisms, etc.) and the possible presence of anti-
drug antibodies if the patient is a secondary failure
Regarding the identification of prognostic factors and
mechanisms underlying therapeutic failure, some studies,
especially on TNF-is, have suggested that individual patient’s
characteristics and disease features could predict response
to treatment [11, 12]. However, the conclusions of available
studies are not univocal; in some cases, a correlation between
clinical features and response to treatment has not been
found [13]. Therefore, other factors could have an impact
on clinical response particularly with biological treatment,
among these immunogenicity. However, this has not been
corroborated by the evidence available today [14–17]. Italian
rheumatologists strongly agree with the choice of patients’
characteristics (age, sex, concomitant therapies, body mass
index, life habits, and comorbidity) as prognostic factors
for treatment response. However, with regards to the use of
biological biomarkers [SNPs, micro-RNA, polymorphisms,
and evaluation of antidrug antibodies (ADA)] consensus has
not been reached, even though 60%of the participants agreed
with this item. In fact, Italian rheumatologists have a growing
interest for these complex areas, despite the difficulty in
their use and the absence of validation of these parameters.
Consistent with the Delphi results, the 2016 Target Therapy
Meeting included the identification of biomarkers within
target tissues as one of the primary unmet needs in RA [4].
Concerning ADA, a recent review of the literature
highlights that evidence-based recommendations on how
to guide biologic therapy on the basis of drug levels and
immunogenicity are lacking and that none of the assays
available to detect ADAs are acceptable for routine clinical
use. Therefore, according to the authors, the use of ADA
seems to be indicated essentially to modulate dosage and
route of administration of the drug [18]. In the light of these
considerations and taking into account the availability of the
large number of drugs with different mechanisms of action,
changing the therapeutic strategy can be an acceptable choice
in a real clinical setting of secondary failures.
Disease Remission (Table 5). Statement 10.3. The “treat to
target” approach has been proposed since 2010 for RA
patients, with remission as the best treatment outcome
possible. However, high heterogeneity in the definitions of
disease remission exists in clinical practice. I believe that to
achieve complete remission it would be necessary to reach
immunological remission.
Another controversial aspect in the management of RA
is the concept of remission. According to recent recommen-
dations, remission is a primary target of RA treatment [19].
However, the rate of remission of patients on biological drugs
is only 20-30% in established disease [20].
The American College of Rheumatology (ACR) and
EULARhave recently developed new remission criteria based
on a Boolean approach or on an approach based on SDAI and
CDAI criteria, which provide continuous numerical scales
that reflect the activity of the disease and are closely related
to the absence of residual inflammatory activity [19].
Furthermore, Baker et al. assert that remission as defined
by ACR/EULAR is not the optimal particularly in clinical
practice and in nonresearch settings and it does not always
equate to absence of disease [21].
Consistent with this evidence, participants agreed that
achieving full persistent disease remission is an unmet need
in the treatment of RA.
Some reasons could be the absence of validated biomark-
ers that can measure remission [21] and the heterogeneity
of the concept of remission as it may be interpreted from
clinical, radiological, or immunological/molecular points of
view.
Consistent with this heterogeneity, in 97% of cases par-
ticipants identified both clinical and radiological remission
as those preferentially used in clinical practice. Regarding
the concept of immunological remission, almost 30% of the
participants did not identify it as preferential, underlining
how the definition of immunological remission is still unclear
and is not supported by robust evidence. Although some
evidence concerning the use of T-cell subset to objectify
the phenotype of patients in remission has introduced the
concept of immunological remission [20], objective criteria
for defining remission that includes immunologic assessment
of the disease state are absent [22] and the concept of
molecular remission still remains elusive [10]. Furthermore,
the 2016 Target Therapy Meeting identified the development
of molecular definitions of disease remission as a primary
unmet scientific need in RA [4].
5. Conclusion
Despite available therapies, many unmet medical needs are
still present in the treatment of RA patients. By address-
ing them, we could improve patients’ RA management. In
particular, the high heterogeneity among both the patients
and the disease as well as the poor achievement of clinical
remission can lead to the observation that additional drugs
will be needed to meet the needs of all patients and health
care professionals.
Data Availability
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